tirzepatide muscle Is Causing Loss? Inside the SURMOUNT-1 Sub-Study | Dr. Dan Chronic treatment with tirzepatide augments

Effective across multiple GI pathology models including ulcers, fistulas, and inflammatory bowel disease No reported toxicity even at high doses in preclinical studies Mechanism involves interaction with NO system, dopamine system, and prostaglandin pathways The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration2011Tissue Repair BPC 157 accelerates healing of transected rat Achilles tendon and stimulates tendocyte growth in vitro

Thats why GLP-1s show up in clinical trials for cardiovascular disease, kidney disease, heart failure, dementia, NASH (fatty liver), and cancer

Understanding this context does not make compounded GLP-1 programs inherently better or worse than FDA-approved alternatives

Biological & Pharmaceutical Bulletin, 36(8), 1247-1252.